Overcoming Acquired PD-1/PD-L1 Resistance with CD38 Blockade.
Overexpression of CD38 after PD-1/PD-L1 blockade increases extracellular adenosine levels and may contribute to acquired resistance to anti-PD-1/PD-L1 therapy. Cancer Discov; 8(9); 1066-8. ©2018 AACRSee related article by Chen et al., p. 1156.